Who are TDT067's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): FTY720, fingolimob (FTY), Group S+T, Placebo to ozanimod, JYB1904, Elizaria®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tdt067.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

TDT067 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TDT067 (TDT067) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: S1P1 receptor modulator. Area: Autoimmune diseases.

phase 3 S1P1 receptor modulator S1P1 Autoimmune diseases Small molecule Live · refreshed every 30 min

Target snapshot

TDT067 (TDT067) — Celtic Pharma Development Services. TDT067 is a small molecule that targets the S1P1 receptor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
TDT067 TARGET	TDT067	Celtic Pharma Development Services	phase 3	S1P1 receptor modulator	S1P1
FTY720	FTY720	Novartis Pharmaceuticals	marketed	Sphingosine-1-phosphate receptor modulator; Immunomodulator	Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)
fingolimob (FTY)	fingolimob (FTY)	University Hospital, Clermont-Ferrand	marketed	Sphingosine-1-phosphate receptor modulator	S1P1 receptor (sphingosine-1-phosphate receptor 1)
Group S+T	Group S+T	Huazhong University of Science and Technology	marketed	S1P receptor modulator	S1P1
Placebo to ozanimod	Placebo to ozanimod	Celgene	phase 3	Sphingosine-1-phosphate (S1P) receptor modulator	S1P1 and S1P5 receptors
JYB1904	JYB1904	Jemincare	phase 3	S1P1 receptor antagonist	S1P1
Elizaria®	Elizaria®	AO GENERIUM	phase 3	S1P receptor modulator	S1P1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (S1P1 receptor modulator class)

AbbVie · 1 drug in this class
Archigen Biotech Limited · 1 drug in this class
AstraZeneca · 1 drug in this class
BioLineRx, Ltd. · 1 drug in this class
Bright Minds Biosciences Pty Ltd · 1 drug in this class
Celtic Pharma Development Services · 1 drug in this class
Daewoong Pharmaceutical Co. LTD. · 1 drug in this class
Eric Stephen Winer, MD · 1 drug in this class
Ferrer Internacional S.A. · 1 drug in this class
GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TDT067 — Competitive Intelligence Brief. https://druglandscape.com/ci/tdt067. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing